Breaking News, Collaborations & Alliances

PharmaBlock Sciences Partners with Shouyao Holdings

Will support CMC development and manufacturing of Shouyao’s second-generation ALK inhibitor for non-small cell lung cancer.

Author Image

By: Charlie Sternberg

Associate Editor

PharmaBlock Sciences (Nanjing) Inc., an innovative chemistry products and services provider throughout the pharmaceutical R&D process and commercialization, and Shouyao Holdings Co., Ltd., a biopharmaceutical company focusing on innovative tumor and diabetes drug development, have entered a strategic partnership for the CMC development and manufacturing of Shouyao’s leading program, a second-generation ALK inhibitor for non-small cell lung cancer (SY-707).   Shouyao has 16 clinical approvals...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters